Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Verve Therapeutics, a clinical-stage biotechnology company focused on developing genetic medicines for cardiovascular disease, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference. The company's co-founder and CEO, Sekar Kathiresan, M.D., will engage in a fireside chat on Wednesday, February 5, 2025 at 9 a.m. ET in New York.
The event will be accessible via a live webcast through the investor section of Verve's website at www.vervetx.com. For those unable to attend live, the presentation will remain archived on the website for 90 days following the event.
Verve Therapeutics, un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di terapie genetiche per le malattie cardiovascolari, ha annunciato la propria partecipazione al prossimo Guggenheim Securities SMID Cap Biotech Conference. Il co-fondatore e CEO dell'azienda, Sekar Kathiresan, M.D., parteciperà a una chiacchierata informale mercoledì 5 febbraio 2025 alle 9 a.m. ET a New York.
L'evento sarà accessibile tramite una diretta web nella sezione investitori del sito di Verve all'indirizzo www.vervetx.com. Per coloro che non potranno partecipare live, la presentazione rimarrà archiviata sul sito per 90 giorni dopo l'evento.
Verve Therapeutics, una compañía biotecnológica en etapa clínica enfocada en el desarrollo de medicamentos genéticos para enfermedades cardiovasculares, ha anunciado su participación en la próxima Conferencia Biotech SMID Cap de Guggenheim Securities. El cofundador y CEO de la compañía, Sekar Kathiresan, M.D., participará en una charla informal el miércoles 5 de febrero de 2025 a las 9 a.m. ET en Nueva York.
El evento será accesible a través de una transmisión en vivo en la sección para inversores del sitio web de Verve en www.vervetx.com. Para quienes no puedan asistir en vivo, la presentación permanecerá archivada en el sitio web durante 90 días después del evento.
Verve Therapeutics는 심혈관 질환을 위한 유전자 치료제를 개발하는 임상 단계의 생명공학 회사로, 가까운 구겐하임 증권 SMID 캡 생명공학 컨퍼런스에 참여한다고 발표했습니다. 회사의 공동 창립자이자 CEO인 Sekar Kathiresan, M.D.는 2025년 2월 5일 수요일 오전 9시 ET에 뉴욕에서 진행되는 파이어사이드 차트에 참여할 예정입니다.
이 행사는 Verve 웹사이트의 투자자 섹션을 통해 라이브 웹캐스트로 제공됩니다. 라이브에 참석할 수 없는 분들을 위해 프레젠테이션은 이벤트 이후 90일 동안 웹사이트에 아카이브됩니다.
Verve Therapeutics, une entreprise de biotechnologie en phase clinique axée sur le développement de médicaments génétiques pour les maladies cardiovasculaires, a annoncé sa participation à la prochaine Conférence Biotech SMID Cap de Guggenheim Securities. Le co-fondateur et CEO de l’entreprise, Sekar Kathiresan, M.D., participera à une discussion informelle le mercredi 5 février 2025 à 9 h ET à New York.
L'événement sera accessible via un webinaire en direct sur la section investisseur du site de Verve à l'adresse www.vervetx.com. Pour ceux qui ne pourront pas assister en direct, la présentation restera archivée sur le site pendant 90 jours après l'événement.
Verve Therapeutics, ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung genetischer Medikamente für Herz-Kreislauf-Erkrankungen konzentriert, hat seine Teilnahme an der bevorstehenden Guggenheim Securities SMID Cap Biotech Conference bekannt gegeben. Der Mitgründer und CEO des Unternehmens, Sekar Kathiresan, M.D., wird am Mittwoch, den 5. Februar 2025, um 9 Uhr ET in New York an einem Fireside-Chat teilnehmen.
Die Veranstaltung wird über einen Live-Stream im Investorenbereich der Verve-Website unter www.vervetx.com zugänglich sein. Für diejenigen, die nicht live teilnehmen können, wird die Präsentation 90 Tage nach der Veranstaltung auf der Website archiviert bleiben.
- None.
- None.
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 9 a.m. ET in New York.
A live webcast will be available in the investor section of the company’s website at www.vervetx.com. The webcast will be archived for 90 days following the presentation.
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The company’s lead programs –VERVE-102, VERVE-201, and VERVE-301 – target the three cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia (HoFH). VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels. Lp(a) is a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis. For more information, please visit www.VerveTx.com.
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
FAQ
When is Verve Therapeutics (VERV) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How can investors watch Verve Therapeutics' (VERV) Guggenheim Conference presentation?
How long will VERV's Guggenheim Conference presentation be available for replay?
Who will represent Verve Therapeutics (VERV) at the Guggenheim SMID Cap Biotech Conference?
